Healthcare
Live Price
Offline$307.80
+2.21% today
1Y Change
-17.66%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stryker Corporation (SYK) is a Healthcare stock with a market cap of $112.88B and listed on NYSE. The stock last traded around $307.80 and down 17.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +11.2%, EPS growth of +8.0%, a dividend yield of 1.2%. What stands out right now is revenue +11.2%, EPS +8.0%, free cash flow +22.8% with operating margin 21.3% and ROIC 9.8%. The dividend is present but secondary, with a yield around 1.2%. Valuation already assumes a fairly strong business story at P/E 33.8 and price/sales 4.5. Stock Foundry combines SYK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYK Max Drawdown
-29.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.1B
-7.3% YoY
FY Net Income
$2.0B
-15.4% YoY
Free Cash Flow
$2.7B
+34.5% YoY
Revenue Growth
+11.2%
EPS Growth
+8.0%
Gross Margin
63.7%
Net Margin
13.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 25.1B | 22.6B | 20.5B | 18.4B | 17.1B |
| Gross Profit | 16.1B | 14.0B | 12.5B | 11.0B | 10.7B |
| Operating Income | 4.9B | 5.1B | 4.3B | 3.7B | 3.8B |
| EBITDA | 6.3B | 4.9B | 5.1B | 4.0B | 3.6B |
| Net Income | 3.2B | 3.0B | 3.2B | 2.4B | 2.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.0B | 3.7B | 3.0B | 1.8B | 2.9B |
| Total Assets | 47.8B | 43.0B | 39.9B | 36.9B | 34.6B |
| Total Liabilities | 25.4B | 22.3B | 21.3B | 20.3B | 19.8B |
| Shareholder Equity | 22.4B | 20.6B | 18.6B | 16.6B | 14.9B |
| Total Debt | 14.9B | 14.1B | 13.5B | 13.5B | 12.9B |
| Net Debt | 10.8B | 10.5B | 10.5B | 11.7B | 10.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3.3B
+24.4% YoY
Capital Expenditures
525M
+10.7% YoY
Free Cash Flow
2.7B
+34.5% YoY
Key ratios
Gross Margin
63.7%
Operating Margin
21.3%
Net Margin
13.2%
ROE
15.2%
Debt / Equity
0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.